These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 31672556)
21. Transformative therapies for rare CFTR missense alleles. Oliver KE; Han ST; Sorscher EJ; Cutting GR Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041 [TBL] [Abstract][Full Text] [Related]
22. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841 [TBL] [Abstract][Full Text] [Related]
23. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Mall MA; Mayer-Hamblett N; Rowe SM Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331 [TBL] [Abstract][Full Text] [Related]
24. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
34. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
35. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Mesbahi M; Shteinberg M; Wilschanski M; Hatton A; Nguyen-Khoa T; Friedman H; Cohen M; Escabasse V; Le Bourgeois M; Lucidi V; Sermet-Gaudelus I; Bassinet L; Livnat G J Cyst Fibros; 2017 Jan; 16(1):45-48. PubMed ID: 27659740 [TBL] [Abstract][Full Text] [Related]
36. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441 [TBL] [Abstract][Full Text] [Related]
37. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772 [TBL] [Abstract][Full Text] [Related]
38. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Saiman L Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086 [TBL] [Abstract][Full Text] [Related]
39. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
40. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]